# Cl-PEG6-acid

**Cat. No.:** HY-138411

**CAS No.:** 2365309-92-6

**Molecular Formula:** $C_{14}H_{27}ClO_8$

**Molecular Weight:** 358.81

**Target:** PROTAC Linkers

**Pathway:** PROTAC

**Storage:**

| | | |
|---|---|---|
| Pure form | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : ≥ 100 mg/mL (278.70 mM)

* "≥" means soluble, but saturation unknown.

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.7870 mL | 13.9350 mL | 27.8699 mL |
| 5 mM | 0.5574 mL | 2.7870 mL | 5.5740 mL |
| 10 mM | 0.2787 mL | 1.3935 mL | 2.7870 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

Cl-PEG6-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

**$IC_{50}$ & Target**

PEGs

**In Vitro**

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA